What is the role of combined target therapies and radical nephrectomy in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 05, 2019
  • Author: Richard A Santucci, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Sorafenib and sunitinib are vascular endothelial growth factor receptor inhibitors that are now FDA-approved for treating metastatic RCC. They have demonstrated promising initial results and can be used before or after radical nephrectomy, depending on the patient's general health. Other targeted treatments have been through phase II and III trials, with promising initial results.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!